The impact of HPV genotypes on survival in HPV-positive oropharyngeal squamous cell carcinomas: a systematic review
| Autor: | Christian Grønhøj, Anne Skovvang, Martin Garset-Zamani, Amanda F. Carlander, Christian von Buchwald, Jakob Schmidt Jensen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Hpv genotypes medicine.medical_specialty Genotype Cell Alphapapillomavirus 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Oropharyngeal squamous cell carcinoma 030223 otorhinolaryngology Human papillomavirus 16 business.industry HPV Positive Papillomavirus Infections virus diseases General Medicine Survival Analysis female genital diseases and pregnancy complications Oropharyngeal Neoplasms medicine.anatomical_structure Otorhinolaryngology 030220 oncology & carcinogenesis Carcinoma Squamous Cell business |
| Zdroj: | Acta Oto-Laryngologica. 141:724-728 |
| ISSN: | 1651-2251 0001-6489 |
| DOI: | 10.1080/00016489.2021.1927173 |
| Popis: | Patients with HPV-positive (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) are known to have a better prognosis compared to patients with HPV-negative OPSCCs. To investigate the impact of specific HPV genotypes on survival in HPV + OPSCC. A systematic search of PubMed and Embase for studies addressing the association between specific HPV genotypes and survival among patients with OPSCC was performed. Six studies (n = 1385 patients) published between 2013 and 2017 were included. Five studies (n = 1290 patients) found a better survival among HPV16 cases compared to other high-risk (HR) HPV genotypes (HPV 33, 18, 35, 31, 39, 52, 59, 45, 56, 67, 29, and 58), of which three studies (n = 933 patients) reached significant results. Two of these studies reported a five-year overall survival (OS) of 64.6% and 71.4% in HPV16 OPSCCs vs. 45.6% and 57.1% in HR non-HPV16 OPSCCs (p = .001 and p = .010, respectively), and the last study found a better OS among HPV16 cases with a hazard ratio (HR) of 0.35, 95%. CI [0.14;0.85], p = .02. Our findings indicate a favorable prognosis among patients with HPV16 OPSCC compared with HR non-HPV16 OPSCC. These results may be important when designing future trials and in the planning of follow-up regimes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|